AbbVie's Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis
Shots:
- The CHMP positive opinion is based on P-III SELECT program including SELECT-NEXT- SELECT-BEYOND- SELECT-MONOTHERAPY- SELECT-COMPARE and SELECT-EARLY assessing Rinvoq in 4-400+ patients with mod. to sev. active RA
- In P-III studies- Rinvoq improved signs and symptoms of RA- inhibited radiographic progression and improved physical function- both as a monothx. and in combination with conventional synthetic DMARDs
- Rinvoq is a selective and reversible JAK inhibitor- currently under review with health authorities globally to treat mod. to sev. active RA and being evaluated in P-III studies for multiple immune-mediated inflammatory diseases
Click here to read full press release/ article | Ref: AbbVie | Image: AbbVie
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com